152 related articles for article (PubMed ID: 37770525)
1. Cost-effectiveness of 2-[
Naghavi-Behzad M; Gerke O; Kodahl AR; Vogsen M; Asmussen JT; Weber W; Hildebrandt MG; Kidholm K
Sci Rep; 2023 Sep; 13(1):16315. PubMed ID: 37770525
[TBL] [Abstract][Full Text] [Related]
2. Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
Naghavi-Behzad M; Vogsen M; Vester RM; Olsen MMB; Oltmann H; Braad PE; Asmussen JT; Gerke O; Vach W; Kidholm K; Kodahl AR; Weber W; Hildebrandt MG
Br J Cancer; 2022 May; 126(9):1271-1279. PubMed ID: 35013575
[TBL] [Abstract][Full Text] [Related]
3. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
[TBL] [Abstract][Full Text] [Related]
4. 2-[
Vogsen M; Naghavi-Behzad M; Harbo FG; Jakobsen NM; Gerke O; Asmussen JT; Nissen HJ; Dahlsgaard-Wallenius SE; Braad PE; Jensen JD; Ewertz M; Hildebrandt MG
Sci Rep; 2023 Apr; 13(1):5552. PubMed ID: 37019987
[TBL] [Abstract][Full Text] [Related]
5. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
7. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
8. Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of
Moser R; Pfeiffer S; Cala L; Klein E; Kiechle M; Behzadi ST; Fallenberg E; Combs SE; Weber W; Borm KJ
J Nucl Med; 2024 Jun; 65(6):845-850. PubMed ID: 38637138
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.
De Giorgi U; Mego M; Rohren EM; Liu P; Handy BC; Reuben JM; Macapinlac HA; Hortobagyi GN; Cristofanilli M; Ueno NT
J Nucl Med; 2010 Aug; 51(8):1213-8. PubMed ID: 20660382
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer.
Naghavi-Behzad M; Oltmann HR; Alamdari TA; Bülow JL; Ljungstrøm L; Braad PE; Asmussen JT; Vogsen M; Kodahl AR; Gerke O; Hildebrandt MG
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439232
[TBL] [Abstract][Full Text] [Related]
11. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
12.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
[TBL] [Abstract][Full Text] [Related]
14.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
16. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
Piperkova E; Raphael B; Altinyay ME; Castellon I; Libes R; Sandella N; Heiba S; Abdel-Dayem H
Clin Nucl Med; 2007 Jun; 32(6):429-34. PubMed ID: 17515747
[TBL] [Abstract][Full Text] [Related]
17.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
18. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
[TBL] [Abstract][Full Text] [Related]
19. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia.
Vos FJ; Bleeker-Rovers CP; Kullberg BJ; Adang EM; Oyen WJ
J Nucl Med; 2011 Nov; 52(11):1673-8. PubMed ID: 21984799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
